DE60237704D1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden - Google Patents

Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Info

Publication number
DE60237704D1
DE60237704D1 DE60237704T DE60237704T DE60237704D1 DE 60237704 D1 DE60237704 D1 DE 60237704D1 DE 60237704 T DE60237704 T DE 60237704T DE 60237704 T DE60237704 T DE 60237704T DE 60237704 D1 DE60237704 D1 DE 60237704D1
Authority
DE
Germany
Prior art keywords
hiv
antibodies
antibody fragments
nucleic acids
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237704T
Other languages
English (en)
Inventor
Dimiter S Dimitrov
Maxime Moulard
Xiadong Xiao
Yuuei Shu
Sanjay K Phogat
Mei-Yun Zhang
Dennis Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOVERNMENT OF US SECRETARY
US Department of Health and Human Services
Scripps Research Institute
Original Assignee
GOVERNMENT OF US SECRETARY
US Department of Health and Human Services
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOVERNMENT OF US SECRETARY, US Department of Health and Human Services, Scripps Research Institute filed Critical GOVERNMENT OF US SECRETARY
Application granted granted Critical
Publication of DE60237704D1 publication Critical patent/DE60237704D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60237704T 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden Expired - Lifetime DE60237704D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970901P 2001-10-16 2001-10-16
PCT/US2002/033165 WO2003033666A2 (en) 2001-10-16 2002-10-16 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes

Publications (1)

Publication Number Publication Date
DE60237704D1 true DE60237704D1 (de) 2010-10-28

Family

ID=23286644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237704T Expired - Lifetime DE60237704D1 (de) 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Country Status (7)

Country Link
US (2) US7223844B2 (de)
EP (1) EP1450857B1 (de)
AT (1) ATE481109T1 (de)
AU (1) AU2002337885B1 (de)
CA (1) CA2463931A1 (de)
DE (1) DE60237704D1 (de)
WO (1) WO2003033666A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951947B2 (en) 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP2278020A3 (de) * 2002-04-09 2011-05-11 Nationwide Children's Hospital, Inc. Antikörpergentransfer und rekombinantes AAV dafür
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (de) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
US20050003347A1 (en) * 2003-05-06 2005-01-06 Daniel Calarese Domain-exchanged binding molecules, methods of use and methods of production
CA2553788A1 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
JP2007529718A (ja) 2004-03-12 2007-10-25 ザ スクリップス リサーチ インスティチュート 蛋白質活性の検出および定量のための蛍光シグナル発光型生細胞バイオセンサー分子ならびに色素
WO2005111621A2 (en) * 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US8647818B2 (en) 2005-02-18 2014-02-11 UAB Research Foundation, University of Alabama—Birmingham Molecular scaffolds for HIV-1 immunogens
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
EP2054086A1 (de) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG Konjugat aus einem antikörper gegen ccr5 und einem antifusogenen peptid
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0717512A2 (pt) 2006-09-29 2013-11-19 Hoffmann La Roche Anticorpos contra ccr5 e usos dos mesmos
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
AU2010234031B2 (en) 2009-04-07 2015-10-01 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2807269A1 (en) * 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
AU2011312562B2 (en) * 2010-09-27 2014-10-09 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
EP2681240B1 (de) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalente antigenbindende proteine
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2968520B1 (de) 2013-03-14 2021-05-12 MacroGenics, Inc. Mit einen aktivierungsrezeptor exprimierenden immuneffektorzellen immunreaktive bispezifische moleküle
EP3027755B1 (de) * 2013-08-02 2019-10-09 The Regents of The University of California Manipulation von antiviraler t-zell-immunität durch stammzellen und chimäre antigenrezeptoren
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
EP3080156A1 (de) * 2013-12-10 2016-10-19 F. Hoffmann-La Roche AG Verwendung der bindungsdomäne einer untereinheit einer struktur mit mehreren untereinheiten zur gezielten verabreichung pharmazeutischer wirkstoffe an die struktur mit mehreren untereinheiten
US10100115B2 (en) 2014-02-14 2018-10-16 Macrogenics, Inc. Methods for the treatment of vascularizing cancers
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2018237357A1 (en) 2017-06-22 2018-12-27 University Of Maryland, Baltimore HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV
WO2019173794A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
AU3662293A (en) 1992-02-10 1993-09-03 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0675904B1 (de) 1992-09-30 2003-03-05 The Scripps Research Institute Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
US5925741A (en) * 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
ES2166779T3 (es) * 1993-05-07 2002-05-01 Bio Merieux Inc Complejos inmunogenicos del hiv.
AU8083594A (en) * 1993-10-19 1995-05-08 Scripps Research Institute, The Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2204863A1 (en) 1994-11-10 1996-05-23 Dennis R. Burton Method for identifying protective antigens for eliciting neutralizing antibodies
ES2332435T3 (es) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
US6135941A (en) * 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
WO2000040616A1 (en) 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
AU765218B2 (en) 1999-03-16 2003-09-11 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The A novel chimeric protein for prevention and treatment of HIV infection
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
IL154991A0 (en) * 2000-09-22 2003-10-31 Univ Duke Immunogen comprising ligand bound hiv envelope protein
US7666424B2 (en) * 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003092630A2 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (de) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper

Also Published As

Publication number Publication date
EP1450857A4 (de) 2006-01-18
WO2003033666A2 (en) 2003-04-24
US20040259075A1 (en) 2004-12-23
CA2463931A1 (en) 2003-04-24
EP1450857A2 (de) 2004-09-01
US7378093B2 (en) 2008-05-27
US20070212349A1 (en) 2007-09-13
EP1450857B1 (de) 2010-09-15
AU2002337885B1 (en) 2003-04-28
US7223844B2 (en) 2007-05-29
WO2003033666A3 (en) 2004-06-24
ATE481109T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
DE60237704D1 (de) Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2005000246A3 (en) Methods and compositions for treating rheumatoid arthritis
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
WO2003048083A3 (en) Antibodies against monocyte chemotactic proteins
DE502005006022D1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
WO2005121175A3 (en) Env polypeptide complexes and methods of use
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
TW200621754A (en) Chemical compounds
EP1603949B8 (de) Antikörper gegen il21-rezeptor und deren verwendung
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
PE20071055A1 (es) Anticuerpos anti mn
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
WO2022032006A3 (en) Il2rb binding molecules and methods of use
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
Walker et al. High-throughput B cell epitope determination by next-generation sequencing
DE60135158D1 (de) Antagonisten des ige-rezeptors
DK1567018T3 (da) Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2022081460A8 (en) Biosynthetic materials and methods for multidirectional biotransportation